Teva launches generic kidney disease treatment in US

Zemplar is an active form of vitamin D to treat chronic kidney disease with annual US sales of $115 million.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has launched generic Zemplar (paricalcitol) tablets in the US. As the first to file, Teva has 180 days of marketing exclusivity.

Zemplar, sold by AbbVie Inc. (NYSE: ABBV) is an active form of vitamin D used to prevent and treat secondary hyperparathyroidism (increased parathyroid hormone levels) in patients with Stage 3 or Stage 4 chronic kidney disease and in Stage 5 patients on dialysis. Zemplar has $115 million in US annual sales, according to IMS data.

Published by Globes [online], Israel business news - - on October 1, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018